

**ESTUDIO CLÍNICO
DE
PACIENTES CON VIH/SIDA
EN KENIA**

**RESUMEN DEL ESTUDIO CLÍNICO
EN
PACIENTES CON VIH/SIDA TRATADOS CON EL PREPARADO
VIUSID
EN EL INSTITUTO DE INVESTIGACIONES MÉDICAS
DE KENIA (KEMRI)**

Investigador Principal

1. Mr Charles F.L. Mbakaya
MSc (Chemist) - KEMRI

Co-Investigador

1. Mr Wilfred Kisingu, Dip (PHE) - KEMRI

CATALYSIS, S.L. - Marzo 2003

KENIA 2003


Número de Pacientes	34
Tiempo de Tratamiento Terapia	36 meses (3 años) monoterapia con VIUSID

Índice de Supervivencia


- índice de supervivencia de un **82,35%** en **36 meses**

Carga Viral

- En los 36 meses de tratamiento con **VIUSID**, la **carga viral** se reduce un **63%**, pasando de 100.509 a 37.384 copias/ml.
- Cinco de los pacientes (**18,52%**) redujeron la **carga viral** a **128** unidades o **indetectable**.

Carga Viral Media

- En los 36 meses de tratamiento con **VIUSID**, los valores medios de **CD₄** de todos los pacientes tratados se mantienen estables a **> 350 CD₄/ml**.



Efectos Secundarios

- A los **36** meses de estudio clínico, **no** se han detectado **efectos secundarios**.

Eficacia


- gran eficacia de **VIUSID**
- La observación de que **8** pacientes han reducido la carga viral por debajo de **1.000** copias/ml a lo largo de **36** meses de tratamiento, **demuestra** que este producto tiene beneficios a largo plazo para los usuarios, especialmente para aquéllos en las fases iniciales de la evolución de la enfermedad.

- Es significativo que los pacientes que en origen tienen un número bajo de **CD₄** y una **carga viral** alta también se benefician de **VIUSID**.
- ausencia de resistencia con este tratamiento
- normalización de los parámetros bioquímicos: glucosa, ácido úrico, albúmina, creatinina, bilirrubina, transaminasas, colesterol, ...

Calidad de Vida

- normalización de las lesiones genitales y anales, diarreas, fiebres, picores, sudores, dolores de cabeza, infecciones, ...
- mejoría del estado en general

Peso Medio de los 34 Pacientes





KENYA MEDICAL RESEARCH INSTITUTE

P.O. Box 54840, Tel: (02) 722541, Fax(02) 720030, KEMRI, NAIROBI, Kenya, E-mail: Kemrilib @ken.healthnet.org

HIV/AIDS VIUSID STUDY (KENYA)

INTERIM REPORT TO CATALYSIS - SPAIN

ON

THE PILOT CLINICAL STUDY

ON

THE MANAGEMENT OF HUMAN IMMUNODEFICIENCY
VIRUS (HIV) PATIENTS WITH NUTRITIONAL PREPARATION
(VIUSID) AT THE KENYA MEDICAL RESEARCH INSTITUTE
(KEMRI)

PRINCIPAL INVESTIGATORS:

1. Mr. Charles F.L. Mbakaya, MSc (Chemist) -KEMRI

CO-INVESTIGATOR:

1. Mr. Wilfred Kisingu, Dip (PHE) -KEMRI

14th March 2003

INTRODUCTION

It is estimated that 58 million people are infected with HIV/AIDS to-date (WHO, 2001). Of these, 18 million have died, leaving 40 million living with HIV/AIDS, 80% being in Sub-Saharan Africa. In Kenya, 750 people die of AIDS daily and this disease has been declared a National Disaster.

Although there are many methods by which this disease is being managed which include awareness creation, use of condoms, voluntary testing and counselling, prevention of vertical transmission, treatment of opportunistic infections, search for appropriate vaccines and containment of viral replication using ARVs, we at KEMRI have particularly taken a keen interest in the role of nutrition as a potent and under-utilised arsenal in the fight against HIV/AIDS, especially in sub-saharan Africa where malnutrition is rampant.

In this respect, we chose to evaluate VIUSID which as a special nutrient manufactured by Catalysis of Spain contains Honey; Proteins (arginine, Glycine); Vitamins (C, B6, B12, B5, Folic Acid); Minerals (Zinc Sulphate) and adjuvant components (Malic Acid, Glucosamine and Glycyrrhizic Acid). These ingredients have been subjected to molecular activation, thereby enhancing their potency almost 1,000 fold in their role as anti-oxidants. Molecular activation particularly enhances the property of VIUSID in scavenging free radicals which promote oxidative stress; activating and promoting viral replication. The ingredients also have some direct anti-viral activity which together substantially reduces the viral loads in patients using VIUSID.

MATERIALS AND METHODS

Design

This was an open label study

Objective

To rapidly assess the potential benefits of VIUSID as a special nutrient for the management of HIV/AIDS patients with a view to conducting a full scale randomised and placebo-controlled clinical trial to decisively demonstrate the benefits of this product in Kenya and other Sub-Saharan countries.

Methods

The study was subjected to scientific and ethical scrutiny and approved by the Kenya Medical Research Institute to commence in January 2000. In all, 44 persons aged between 20-50 years and at various stages of disease progression were recruited into the study from The Association of People With AIDS (TAPWAK) in Nairobi, 70% of the cohort comprising women who quickly expressed interest when the study was launched.

The patients were both of low and middle socio-economic status. Four women whose husbands had died of AIDS were confirmed HIV negative and weaned from the study. Six patients have succumbed to

AIDS within 36 months of follow-up, eight dropped out of the study for various personal reasons while 27 are still being followed effectively to-date.

Each patient receives his/her monthly supply of VIUSID sachets, three of which are taken daily 8 hours apart in a glass of water, juice or milk.

The patients were clinically reviewed every two weeks and classified each time by their CDC disease staging criteria developed by the CDC (1993). In addition their anthropometric status was assessed every two weeks for 36 months. For each patient, 20 MLs of blood samples were taken at baseline and every 3 months for the following tests:

- 1) Haematology
- 2) Liver/Kidney functions
- 3) Immunology (CD4/8)
- 4) Virology and
- 5) Biochemisry

RESULTS

Tables 1 to 22 below present a summary of the results of the clinical trial as at 3 months of VIUSID intake.

TABLE 1A: CLINICAL CLASSIFICATION OF PATIENTS ACCORDING TO WHO GUIEDELINES

WHO Grading	WEEK						
	0	2	4	6	8	10	12
1	7(21%)	11(32%)	12(35%)	14(41%)	17(50%)	21(62%)	30(88%)
2	6(18%)	14(41%)	15(44%)	12(35%)	13(38%)	12(35%)	3(9%)
3	13(38%)	8(24%)	7(21%)	8(24%)	4(12%)	1(3%)	1(3%)
4	8(24%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 1B: CLINICAL CLASSIFICATION OF PATIENTS ACCORDING TO WHO GUIEDELINES

WHO Grading	WEEK						
	14	16	18	20	22	24	26
1	31(91%)	28(82%)	28(82%)	30(88%)	29(85%)	28(82%)	27(79%)
2	3(9%)	6(18%)	6(18%)	3(9%)	4(12%)	6(18%)	5(15%)
3	0(0%)	0(0%)	0(0%)	1(3%)	1(3%)	0(0%)	2(6%)
4	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 1C: CLINICAL CLASSIFICATION OF PATIENTS ACCORDING TO WHO GUIEDELINES

Grading	WEEK						
	28	30	32	34	36	38	40
1	24(70%)	23(67%)	22(64%)	22(64%)	24(70%)	21(62%)	25(73%)
2	9(27%)	10(30%)	11(33%)	12(36%)	9(27%)	11(33%)	8(24%)
3	1(3%)	1(3%)	1(3%)	0(0%)	1(3%)	2(6%)	1(3%)
4	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 1D: CLINICAL CLASSIFICATION OF PATIENTS ACCORDING TO WHO GUIEDELINES

Grading	WEEK						
	42	44	46	48	50	78	144
1	21(61%)	25(74%)	26(76%)	23(68%)	24(71%)	24(73%)	22(81%)
2	12(35%)	8(24%)	7(21%)	10(29%)	9(26%)	6(18%)	3(11%)
3	1(3%)	1(3%)	1(3%)	1(3%)	1(3%)	3(9%)	2(8%)
4	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 2A: OCCURRENCE OF HEADACHE

Grading	WEEK						
	0	2	4	6	8	10	12
None	17(50%)	27(79%)	31(91%)	33(97%)	33(97%)	32(94%)	33(97%)
Mild	2(6%)	2(6%)	0(0%)	1(3%)	1(3%)	0(0%)	0(0%)
Moderate	8(24%)	2(6%)	2(6%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	7(20%)	3(9%)	1(3%)	0(0%)	0(0%)	2(6%)	1(3%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 2B: OCCURRENCE OF HEADACHE

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	34(100%)	33(97%)	31(91%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	2(6%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 2C: OCCURRENCE OF HEADACHE

Grading	WEEK						
	28	30	32	34	36	38	40
None	34(100%)	34(100%)	32(94%)	33(97%)	33(97%)	32(94%)	32(94%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)	1(3%)
Moderate	0(0%)	0(0%)	2(6%)	1(3%)	0(0%)	0(0%)	1(3%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	2(5%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 2D: OCCURRENCE OF HEADACHE

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	34(100%)	34(100%)	34(100%)	33(97%)	33(100%)	26(96%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(4%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 3A: OCCURRENCE OF ITCHY GENITAL LESIONS

Grading	WEEK						
	0	2	4	6	8	10	12
None	18(53%)	26(76%)	28(82%)	32(94%)	26(76%)	30(88%)	34(100%)
Mild	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	1(3%)	2(6%)	0(0%)	0(0%)	0(0%)	2(6%)	0(0%)
Severe	14(41%)	6(18%)	6(18%)	2(6%)	8(24%)	2(6%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 3B: OCCURRENCE OF ITCHY GENITAL LESIONS

Grading	WEEK						
	14	16	18	20	22	24	26
None	33(97%)	33(97%)	33(97%)	32(94%)	29(85%)	32(94%)	33(97%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	1(3%)	1(3%)	1(3%)	2(6%)	5(15%)	2(6%)	1(3%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 3C: OCCURRENCE OF ITCHY GENITAL LESIONS

Grading	WEEK						
	28	30	32	34	36	38	40
None	33(97%)	31(91%)	32(94%)	32(94%)	32(94%)	31(91%)	32(94%)
Mild	1(3%)	2(6%)	0(0%)	0(0%)	1(3%)	1(3%)	1(3%)
Moderate	0(0%)	1(3%)	2(6%)	2(6%)	1(3%)	2(6%)	1(3%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 3D: OCCURRENCE OF ITCHY GENITAL LESIONS

Grading	WEEK						
	42	44	46	48	50	78	144
None	33(97%)	33(97%)	34(100%)	32(94%)	33(97%)	33(100%)	26(96%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(4%)
Moderate	1(3%)	1(3%)	0(0%)	2(6%)	1(3%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 4A: OCCURRENCE OF DIARRHOEA

Grading	WEEK						
	0	2	4	6	8	10	12
None	27(79%)	32(94%)	30(88%)	32(94%)	34(100%)	34(100%)	34(100%)
Mild	1(3%)	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	2(6%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	4(12%)	1(3%)	3(9%)	2(6%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 4B: OCCURRENCE OF DIARRHOEA

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(97%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 4C: OCCURRENCE OF DIARRHOEA

Grading	WEEK						
	28	30	32	34	36	38	40
None	33(97%)	34(100%)	33(97%)	34(100%)	33(97%)	34(100%)	34(100%)
Mild	1(3%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 4D: OCCURRENCE OF DIARRHOEA

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	33(97%)	34(100%)	34(100%)	33(97%)	33(100%)	27(100%)
Mild	0(0%)	1(3%)	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(0%)

TABLE 5A: OCCURRENCE OF NIGHT SWEATS

Grading	WEEK						
	0	2	4	6	8	10	12
None	13(38%)	26(76%)	26(76%)	27(79%)	28(82%)	32(94%)	33(97%)
Mild	1(3%)	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)
Severe	20(58%)	8(24%)	7(21%)	7(21%)	5(15%)	2(6%)	1(3%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 5B: OCCURRENCE OF NIGHT SWEATS

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 5C: OCCURRENCE OF NIGHT SWEATS

Grading	WEEK						
	28	30	32	34	36	38	40
None	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 5D: OCCURRENCE OF NIGHT SWEATS

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	34(100%)	33(97%)	34(100%)	33(97%)	33(100%)	27(96%)
Mild	0(0%)	0(0%)	1(3%)	0(0%)	1(3%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(4%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	28(0%)

TABLE 6A: OCCURRENCE OF ITCHY ANAL LESIONS

Grading	WEEK						
	0	2	4	6	8	10	12
None	26(76%)	32(94%)	31(91%)	33(97%)	33(97%)	32(94%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)
Severe	8(24%)	2(6%)	3(9%)	1(3%)	1(3%)	1(3%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 6B: OCCURRENCE OF ITCHY ANAL LESIONS

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	33(97%)	33(97%)	33(97%)	33(97%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	1(3%)	1(3%)	1(3%)	1(3%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 6C: OCCURRENCE OF ITCHY ANAL LESIONS

Grading	WEEK						
	28	30	32	34	36	38	40
None	34(100%)	33(97%)	33(97%)	34(100%)	34(100%)	32(94%)	33(97%)
Mild	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	1(3%)	1(3%)
Moderate	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)	1(3%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 6D: OCCURRENCE OF ITCHY ANAL LESIONS

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	33(97%)	34(100%)	33(97%)	33(97%)	33(100%)	26(96%)
Mild	0(0%)	0(0%)	0(0%)	1(3%)	1(3%)	0(0%)	1(4%)
Moderate	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(0%)	27(100%)

TABLE 7A: OCCURRENCE OF ITCHY SKIN

Grading	WEEK						
	0	2	4	6	8	10	12
None	21(62%)	26(76%)	25(73%)	32(94%)	32(94%)	30(88%)	31(91%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(3%)
Moderate	1(3%)	1(3%)	3(9%)	0(0%)	0(0%)	1(3%)	2(6%)
Severe	12(35%)	7(21%)	6(18%)	2(6%)	2(6%)	3(9%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 7B: OCCURRENCE OF ITCHY SKIN

Grading	WEEK						
	14	16	18	20	22	24	26
None	33(97%)	31(91%)	32(94%)	31(91%)	29(85%)	33(97%)	32(94%)
Mild	1(3%)	3(9%)	1(3%)	3(9%)	3(9%)	1(3%)	1(3%)
Moderate	0(0%)	0(0%)	1(3%)	0(0%)	1(3%)	0(0%)	1(3%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 7C: OCCURRENCE OF ITCHY SKIN

Grading	WEEK						
	28	30	32	34	36	38	40
None	32(94%)	29(85%)	30(88%)	33(1%)	32(94%)	29(85%)	31(91%)
Mild	1(3%)	4(12%)	1(3%)	1(3%)	0(0%)	4(12%)	0(0%)
Moderate	1(3%)	1(3%)	3(9%)	0(0%)	2(6%)	1(3%)	3(9%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 7D: OCCURRENCE OF ITCHY SKIN

Grading	WEEK						
	42	44	46	48	50	78	144
None	26(76%)	32(94%)	30(88%)	31(91%)	30(88%)	30(91%)	23(82%)
Mild	7(21%)	2(6%)	2(6%)	3(9%)	4(12%)	1(3%)	3(12%)
Moderate	1(3%)	0(0%)	2(6%)	0(0%)	0(0%)	2(6%)	1(4%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 8A: OCCURRENCE OF ORAL THRUSH

Grading	WEEK						
	0	2	4	6	8	10	12
None	24(70%)	30(88%)	32(94%)	33(97%)	33(97%)	33(97%)	34(100%)
Mild	1(3%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	4(12%)	3(9%)	2(6%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	5(15%)	0(0%)	0(0%)	1(3%)	1(3%)	1(3%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 8B: OCCURRENCE OF ORAL THRUSH

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	33(97%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 8C: OCCURRENCE OF ORAL THRUSH

Grading	WEEK						
	28	30	32	34	36	38	40
None	34(100%)	33(97%)	34(100%)	32(94%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	2(6%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 8D: OCCURRENCE OF ORAL THRUSH

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27 (100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 9A: OCCURRENCE OF FEVER

Grading	WEEK						
	0	2	4	6	8	10	12
None	20(59%)	33(97%)	31(91%)	32(94%)	32(94%)	32(94%)	34(100%)
Mild	4(12%)	0(0%)	2(6%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	7(21%)	1(3%)	1(3%)	0(0%)	0(0%)	1(3%)	0(0%)
Severe	3(9%)	0(0%)	0(0%)	2(6%)	2(6%)	1(3%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 9B: OCCURRENCE OF FEVER

Grading	WEEK						
	14	16	18	20	22	24	26
None	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 9C: OCCURRENCE OF FEVER

Grading	WEEK						
	28	30	32	34	36	38	40
None	34(100%)	33(97%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)

TABLE 9D: OCCURRENCE OF FEVER

Grading	WEEK						
	42	44	46	48	50	78	144
None	34(100%)	33(97%)	34(100%)	34(100%)	34(100%)	33(100%)	26(96%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(4%)
Moderate	0(0%)	1(3%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
TOTAL	34(100%)	34(100%)	34(100%)	34(100%)	34(100%)	33(100%)	27(100%)

TABLE 10: IMMUNOLOGICAL PARAMETERS AS AT 36 MONTHS OF VIUSID INTAKE

ID	CD4/8 (1)	CD4/8 (2)	CD4/8 (3)	CD4/8 (4)	CD4/8 (5)	CD4/8 (6)	CD4/8 (9)	CD4/8 (10)	CD4 (1)	CD4 (2)	CD4 (3)	CD4 (4)	CD4 (5)	CD4 (6)	CD4 (7)	CD4 (9)	CD4 (10)
1	0.25	0.27	0.27	0.22	0.18	0.15	0.12	Absent	223	250	269	231	213	170	170	60	Absent
4	0.58	0.53	0.48	0.53	0.48	0.46	0.31	0.23	680	423	498	650	632	378	326	332	205
5	0.45	0.54	0.60	0.64	0.63	0.50	0.50	0.50	866	424	800	893	651	600	438	684	620
7	0.07	0.08	0.08	0.08	0.10	0.09	0.19	0.08	398	249	390	313	413	318	400	370	214
8	0.38	0.38	0.37	0.29	0.35	0.29	0.29	0.27	331	331	306	337	397	301	360	225	307
9	0.61	0.73	0.47	0.38	0.37	0.42	0.36	0.37	439	509	550	392	424	401	400	471	400
10	0.33	0.38	0.18	0.15	0.05	0.05	diad	Die d	349	191	384	163	72	70	-	Dea d	Died
13	0.87	0.96	0.86	1.26	0.82	0.67	0.57	0.57	805	788	937	1016	1131	589	676	683	647
14	0.11	0.11	0.10	0.20	0.16	0.14	0.11	0.12	209	228	304	364	320	176	278	215	210
15	0.68	0.56	0.36	0.39	0.46	0.53	0.36	0.38	282	283	333	258	320	304	368	282	270
17	0.95	1.76	0.90	1.09	0.99	0.96	1.12	0.95	971	838	942	754	884	836	872	1016	839
19	0.12	0.13	0.17	0.13	0.13	0.15	0.14	0.15	259	315	359	285	194	240	277	271	173
21	0.14	0.12	0.12	0.11	0.14	0.10	0.15	0.11	236	231	408	171	248	167	247	186	141
22	0.16	0.13	0.12	0.13	0.13	Died	died	Die d	159	116	162	187	196	Die d	died	Die d	Died
25	0.23	0.19	0.21	0.19	0.18	0.16	0.09	0.17	246	242	293	179	174	258	258	174	211
27	1.90	1.73	1.57	1.84	1.70	1.46	1.71	1.37	1339	1252	1292	1336	1517	1304	1325	1777	1271
28	0.24	0.22	0.22	0.20	0.19	0.18	0.15	0.19	331	236	273	458	404	238	240	292	267
29	1.08	1.13	1.16	1.25	1.26	1.48	0.82	0.88	1173	781	809	648	749	597	478	599	717
30	0.30	0.29	0.34	0.34	0.34	0.40	died	Die d	293	257	334	330	330	300	301	Die d	Died
33	0.10	0.13	0.12	0.08	0.09	0.09	0.03	Die d	99	98	107	76	111	115	84	23	Died
34	0.42	0.49	0.42	1.03	0.40	0.32	0.41	0.47	769	498	785	729	681	750	868	826	487
36	0.17	0.22	0.26	0.35	0.16	0.20	died	Die d	123	99	107	95	86	94	-	Die d	Died
37	0.38	0.57	0.32	0.29	0.29	0.27	0.17	0.29	278	272	419	383	349	314	238	125	256
38	0.29	0.23	0.25	0.14	0.22	0.25	0.14	0.15	211	175	218	186	193	154	299	125	115
40	0.46	0.39	0.41	0.52	0.50	0.69	0.57	0.58	538	553	703	576	690	922	900	654	514
41	0.25	0.23	0.30	0.32	0.31	0.31	0.22	0.25	167	217	218	137	165	183	184	129	92
42	0.23	0.23	0.23	0.21	0.19	0.16	0.08	0.20	306	230	346	275	293	162	112	91	97
46	0.08	0.12	0.08	0.12	0.10	0.09	died	Die d	330	644	315	531	435	400	407	Die d	Died
47	0.26	0.34	0.35	0.35	0.36	0.40	0.41	0.35	570	557	544	663	544	540	545	602	588
48	0.04	0.06	0.05	0.06	0.05	0.03	0.04	0.03	111	117	91	118	117	100	84	59	42
54	0.24	0.23	0.34	0.21	0.29	0.23	0.23	0.52	176	213	174	129	192	147	192	194	291
56	0.60	0.41	0.34	0.29	0.30	0.17	0.25	0.29	525	416	519	388	437	295	300	209	212
57	2.40	1.52	1.44	1.25	1.47	1.69	1.26	1.44	438	481	618	691	543	628	650	468	362
59	2.09	2.41	2.13	2.13	2.19	2.54	2.09	2.25	619	737	1055	747	782	919	961	879	879
MEAN	0.51	0.52	0.46	0.49	0.46	0.47	0.47	0.49	436	389	466	432	437	387	392	411	367

Key:

1=Baseline results
 2=3 months results
 3=6 months results
 4=9 months results
 5=12 months results
 6=18 months results
 7=24 months results
 9=30 months results

CD4 (1) = Baseline
 CD4 (2) = 3 months
 CD4 (3) = 6 months
 CD4 (4) = 9 months
 CD4 (5) = 12 months
 CD4 (6) = 18 months
 CD4(7) = 24 months
 CD4(9) = 30 months result
 CD4(10)= 36 months

TABLE 11: HIV/AIDS VIUSID PROJECT (KENYA): INTERIMM VIRAL LOAD CHANGES BY CDC DISEASE CLASSIFICATION AS AT 36 MONTHS

ID	CDC (1)	CDC (10)	VL (1)	VL (2)	VL (3)	VL (4)	VL(5)	VL (6)	VL(7)	VL(8)	VL(9)	VL(10)
1	B	Absent	74350	353858	186078	38000	63700	57416	60,000	61,000	77,783	Absent
4	C	C	67186	24562	111386	84512	169000	67030	21,905	42,140	15,386	37,370
5	B	B	96	88	165	182	234	80	989	1,000	<50	<50
7	C	C	72264	9710	36202	211888	83720	165924	102	828	<50	468
8	B	B	8964	42051	19958	9728	6760	1217	48658	11,672	2,709	12,744
9	B	B	9,252	46545	59522	33440	88140	27773	42595	46,822	42,283	11,997
10	C	DEAD	435485	363812	223744	549024	384020	269438	Dead	Dead	Dead	Died
13	B	B	30626	29610	37800	25232	59800	2323	14,416	15,462	11,972	48,778
14	B	C	112260	140835	321054	142067	89700	10903	0	2,157	17,098	10,300
15	B	B	17302	21496	17312	18240	14560	16236	29,826	20,144	2,198	6,963
17	A	A	8616	29575	29812	12160	19500	11352	0	670	433	263
19	B	C	65424	58266	106096	34960	84240	30000	45,413	30,690	9,571	61,250
21	C	C	95352	297192	15271	171365	243360	22809	916,687	500,000	350,198	87,247
22	C	DEAD	123758	673568	268949	169024	180180	Died	Dead	Dead	Dead	Died
25	C	C	16424	35422	43445	72656	58760	102485	116,182	26,060	15,435	127
27	A	A	9010	2744	1824	1155	2600	1980	0	137	<50	124
28	B	B	129079	52604	64083	50768	90220	29225	127,280	17,372	27,718	39,311
29	B	B	4032	1820	403	2402	208	118	854	4,876	3,041	3,535
30	B	DEAD	14592	232819	7461	7060	5000	4000	15,000	7,000	Dead	Died
33	C	DEAD	256726	205785	185440	221616	*829400	460020	750,000	153,138	48,134	Died
34	A	A	153	235	353	152	7	150	0	75	<50	73
36	C	DEAD	368813	297281	449139	160816	184080	74606	Dead	Dead	Dead	Died
37	C	C	332136	136500	67032	121418	88400	147549	85,482	86,000	8,091	11,052
38	B	B	36518	52466	84924	156560	81640	256344	107,550	54,570	72,845	65,455
40	C	C	11258	34541	9878	58976	23400	58054	60,000	7,256	6,870	8,608
41	C	C	90221	370192	257596	89680	*212420	207425	28,553	397,878	47,193	131,228
42	C	C	108648	382228	318318	183920	110240	400000	31,921	32,000	7,664	7,540
46	C	DEAD	143952	118339	241933	299288	249340	150000	100,000	100,000	Dead	Died
47	C	C	13632	28409	12247	11248	22620	7000	6,000	5,306	10,588	8,376
48	C	C	483048	384703	241984	484546	406120	490000	750,000	500,000	392,903	500,000
54	C	C	109639	123345	191003	115824	88140	70000	53,097	161,978	394	<50
56	C	C	24259	23345	55176	22192	44200	87552	80,000	25,118	24,700	25,000
57	B	B	144110	66301	61797	42560	20800	13999	39,000	16,456	629	11,419
59	A	A	120	252	176	395	234	100	0	90	<50	<50
MEAN			100509	136485	109634	101855	92591	87358	115,053	60,577	41,244	37,384

Key:

- 1=Baseline results
- 2=3 months results
- 3=6 months results
- 4=9 months results
- 5=12 months results
- VL1 =Viral Load at Baseline
- VL2 =Viral Load at 3 months
- VL3 =Viral Load at 6 months
- VL4 =Viral Load at 9 months
- VL5=Viral Load at 12 months
- VL6=Viral Load at 18 months
- VL7= Viral Load at 24 months
- VL8= Viral Load at 27 Months
- VL9= Viral Load at 30 months
- VL10= Viral Load at 36 months
- CDC(1) = patient clinical categorization at baseline by CDC(1993)
- CDC(10)= patient category after 36 months

TABLE 12A: WEIGHT MEASUREMENT (KG)

ID	0	2	4	6	8	10	12
01	61.0	61.0	61.0	62.0	62.0	60.0	60.0
04	52.0	53.0	53.0	53.5	53.0	53.5	53.5
05	79.0	80.0	80.0	79.0	78.5	78.5	78.5
07	64.0	61.0	62.0	63.5	62.0	61.5	61.5
08	73.0	74.0	74.5	73.0	74.0	74.0	75.0
09	52.0	52.0	52.0	53.5	53.5	53.5	55.0
10	59.0	62.0	62.0	62.0	62.0	63.5	64.5
13	55.0	56.5	54.5	54.5	54.5	55.0	55.5
14	56.7	58.0	56.4	56.4	56.4	56.4	56.4
15	64.0	66.0	67.0	67.0	67.0	67.0	67.0
17	89.0	87.0	86.5	87.5	88.0	82.0	82.0
19	64.0	63.0	62.0	62.5	64.0	64.0	64.5
21	63.0	62.0	61.0	59.5	59.0	59.0	59.0
22	41.5	43.5	42.0	42.0	42.5	42.5	42.0
25	57.0	57.0	57.0	58.0	58.0	58.0	58.5
27	74.0	74.5	75.0	75.0	75.5	75.0	74.5
28	67.0	67.0	67.5	69.0	69.5	69.0	69.0
29	56.0	56.5	56.0	56.0	56.0	56.0	57.0
30	92.0	93.0	92.0	91.0	92.0	92.0	92.0
33	57.0	57.0	56.0	56.5	55.5	55.0	56.0
34	69.0	69.0	68.0	69.5	69.0	70.0	71.0
36	61.0	62.0	61.0	61.0	65.0	65.0	64.0
37	56.0	56.0	56.0	57.0	58.5	55.0	53.5
38	69.0	70.5	71.0	71.0	69.0	69.0	70.0
40	64.0	63.0	62.5	62.5	63.0	61.0	63.0
41	57.0	56.5	56.0	56.5	56.5	57.3	56.0
42	62.0	62.0	62.5	63.0	64.5	64.0	67.0
46	64.0	62.0	63.5	62.5	65.0	65.0	66.5
47	58.0	58.0	59.0	60.5	61.0	61.0	62.5
48	51.5	54.0	56.5	57.5	59.5	61.0	63.5
54	76.0	77.5	77.0	77.0	77.0	78.5	80.0
56	53.0	59.0	56.5	57.5	57.5	58.0	59.5
57	107.0	107.0	106.0	106.0	106.0	106.0	106.0
59	90.0	88.5	91.0	91.0	91.5	91.5	91.5
TOTAL	62.4	65.6	65.4	65.7	66.0	65.8	66.3

TABLE 12B: WEIGHT MEASUREMENT (KG)

ID	14	16	18	20	22	24	26
01	59.5	59.5	59.5	59.5	61.5	62.0	61.0
04	52.0	52.0	51.5	52.0	54.0	52.0	51.5
05	80.0	80.0	80.0	80.0	80.0	80.0	80.0
07	60.0	60.0	60.5	60.0	61.0	62.0	62.0
08	75.5	75.5	75.5	75.5	76.0	76.0	76.0
09	54.0	54.0	54.0	54.5	54.5	54.0	54.0
10	64.0	64.0	64.0	64.0	64.0	64.0	64.5
13	54.5	54.5	54.5	54.5	54.0	55.0	55.5
14	56.0	56.5	55.5	54.0	53.0	55.0	55.6
15	60.0	60.5	60.5	60.0	64.0	65.0	65.5
17	82.0	82.5	82.5	82.0	82.0	82.5	81.5
19	65.0	65.0	64.5	65.0	64.0	64.5	64.0
21	61.0	61.0	61.0	61.0	58.5	61.0	61.0
22	43.0	42.5	43.0	43.0	43.0	43.0	43.0
25	58.5	58.5	59.0	58.5	57.5	58.0	57.5
27	74.0	74.0	74.0	74.5	75.5	76.5	76.0
28	69.5	69.5	70.0	69.5	69.5	71.0	70.0
29	57.0	57.0	57.5	57.0	56.5	57.5	57.5
30	101.0	101.0	100.0	100.5	101.0	101.0	101.0
33	59.0	59.0	59.0	59.0	59.0	59.0	59.0
34	60.0	68.0	68.5	68.0	69.5	68.0	68.0
36	64.5	64.5	64.0	65.0	64.5	64.5	64.5
37	56.5	57.0	57.0	56.5	57.0	59.0	58.0
38	73.0	73.5	73.0	73.0	73.5	73.0	72.5
40	64.0	64.0	64.5	64.0	65.5	63.5	64.5
41	54.5	54.5	55.0	54.5	55.5	55.5	55.5
42	65.0	65.0	65.0	65.0	67.0	68.0	68.0
46	64.5	64.5	65.0	64.5	63.5	64.0	64.0
47	59.5	59.0	59.0	59.5	59.5	58.5	59.0
48	64.0	64.0	64.5	65.0	64.0	64.0	63.5
54	78.0	78.0	78.5	78.5	78.0	77.5	77.0
56	59.5	59.5	60.0	59.5	60.5	60.5	59.0
57	101.0	101.0	101.5	101.5	101.0	101.0	101.0
59	90.0	90.5	90.5	90.0	90.5	91.0	91.0
TOTAL	66.1	66.2	66.2	66.1	66.4	66.6	66.5

TABLE 12C: WEIGHT MEASUREMENT (KG)

ID	28	30	32	34	36	38	40
01	63.0	61.0	63.0	62.5	62.0	62.5	64.5
04	52.5	51.5	52.0	52.5	52.0	52.5	52.0
05	79.2	79.5	79.0	79.5	80.5	81.5	82.0
07	62.5	62.0	60.0	61.0	62.0	62.0	61.0
08	76.5	76.5	76.0	76.5	78.0	80.0	79.5
09	55.0	55.5	54.5	55.0	55.5	55.5	55.5
10	65.0	64.5	65.0	64.5	64.0	65.0	65.0
13	54.5	55.0	55.0	54.5	54.5	55.0	55.0
14	55.5	56.5	57.0	55.0	53.0	53.0	55.5
15	65.0	65.5	65.5	66.5	66.5	65.0	69.0
17	82.0	82.0	82.0	82.0	83.0	84.0	87.0
19	68.0	66.0	67.0	67.0	68.0	69.0	69.5
21	59.5	61.0	60.0	63.0	61.0	60.5	59.5
22	43.0	43.0	44.0	43.0	44.0	44.0	44.5
25	57.0	59.0	57.0	59.5	59.0	59.0	58.5
27	77.5	78.0	77.5	77.5	78.0	78.0	78.5
28	69.5	70.0	70.0	70.0	70.5	71.5	72.0
29	57.5	59.5	57.5	59.0	58.0	58.0	59.5
30	91.0	91.5	91.0	91.5	92.0	92.0	92.0
33	58.5	58.5	59.0	59.0	59.0	59.5	58.5
34	69.5	69.0	68.5	69.0	70.0	70.0	70.0
36	64.0	64.5	65.0	65.0	64.0	64.5	65.5
37	57.5	59.5	60.5	60.0	63.0	62.0	61.0
38	74.5	74.0	75.5	76.0	75.5	75.5	75.5
40	64.0	64.0	63.5	63.5	63.5	63.5	63.5
41	56.5	58.0	57.0	58.0	57.0	57.0	57.0
42	71.0	71.0	71.5	71.5	71.5	71.5	71.5
46	62.0	63.5	65.5	63.0	62.0	62.0	61.0
47	59.0	59.5	61.0	61.0	61.0	62.0	62.0
48	63.5	64.0	64.0	64.5	64.0	64.5	64.5
54	78.0	76.5	76.5	78.0	76.5	76.5	78.0
56	57.0	58.0	58.5	60.5	59.0	59.5	59.5
57	101.0	100.5	100.5	100.5	100.0	100.5	101.0
59	96.0	96.5	96.5	96.5	96.5	96.5	97.0
TOTAL	66.6	66.9	66.9	67.2	67.2	67.5	67.8

TABLE 12D: WEIGHT MEASUREMENT (KG) BY WEEK OF REVIEW

ID	0	42	44	46	48	50	52	78	120	144
01	61.0	66.5	67.0	66.0	65.5	65.0	64.0	69.0	52.5	Absent
04	52.0	52.0	52.5	53.5	53.5	52.5	52.5	47.5	50.5	49.0
05	79.0	82.0	81.5	82.0	82.0	81.5	81.5	82.0	86.0	86.2
07	64.0	62.0	62.0	62.0	60.0	60.5	59.5	58.0	60.5	63.0
08	73.0	79.5	80.0	80.5	81.5	83.0	83.0	81.5	81.0	82.0
09	52.0	56.5	56.0	56.0	55.5	56.0	57.0	55.0	51.0	51.0
10	59.0	64.5	65.0	65.0	65.0	65.0	65.0	54.0	Died	Died
13	55.0	56.0	55.0	56.0	56.0	56.0	56.0	55.0	59.5	62.0
14	56.7	57.5	59.5	56.5	54.0	54.0	54.0	55.0	56.0	57.0
15	64.0	70.0	69.0	70.0	68.0	67.0	67.0	70.0	69.0	70.0
17	89.0	88.0	88.0	87.5	90.0	88.0	86.5	91.5	90.0	93.0
19	64.0	69.5	70.0	70.0	70.5	69.5	68.5	68.5	66.0	68.0
21	63.0	61.0	61.0	61.0	59.0	59.5	60.0	60.0	55.0	59.0
22	41.5	45.0	45.0	44.0	45.0	44.0	52.0	Died	Died	Died
25	57.0	59.0	58.0	58.0	56.0	57.0	56.0	58.5	59.0	55.2
27	74.0	77.0	77.0	76.5	77.0	76.5	76.0	73.0	73.5	75.0
28	67.0	72.0	72.0	71.5	72.0	71.5	72.0	70.0	70.0	74.5
29	56.0	59.0	59.0	60.5	57.5	58.0	59.0	60.0	62.5	64.5
30	92.0	101.0	101.0	101.0	101.0	101.0	101.0	92.0	Died	Died
33	57.0	56.0	56.5	56.0	56.0	55.0	54.0	54.0	58.0	Died
34	69.0	72.5	71.5	70.5	70.0	67.0	69.0	65.0	69.0	68.0
36	61.0	65.5	63.5	63.5	64.5	66.0	65.0	58.0	Died	Died
37	56.0	62.0	61.0	61.0	60.0	61.0	60.0	61.0	58.0	62.0
38	69.0	75.0	75.5	76.5	76.5	76.5	76.0	69.0	70.5	72.5
40	64.0	64.0	64.0	65.0	64.5	65.0	65.0	65.0	63.0	63.5
41	57.0	57.0	59.0	59.5	58.5	59.0	59.0	62.0	59.0	57.5
42	62.0	72.5	73.0	72.5	72.5	72.5	72.0	72.5	72.5	73.0
46	64.0	62.0	64.5	64.0	66.0	66.0	67.5	67.0	Died	Died
47	58.0	62.0	62.0	64.0	64.0	67.0	66.0	62.0	63.5	66.5
48	51.5	64.5	65.0	64.0	64.0	65.0	65.5	65.0	64.0	63.5
54	76.0	77.5	79.5	80.0	80.0	80.0	80.0	75.0	71.0	68.0
56	53.0	59.0	59.0	59.0	60.0	60.0	60.5	56.0	56.0	55.0
57	107.0	101.0	100.0	100.0	100.0	100.0	100.0	97.5	102.0	103.0
59	90.0	98.0	97.0	97.0	98.0	98.0	96.0	96.0	90.5	93.0
TOTAL	62.4	68.4	68.5	68.5	68.3	68.3	70.3	67.4	66.9	67.9

Table 13A: HIV/AIDS VIUSID HAEMATOTOLOGY AT BASELINE

Patient IDNO	WBC	LY%	MO%	GR%	LY	MO	GR	RBC	Hgb	Hct	MCV	MCH	MCHC	RDW	HL	MPV
1	3.9	43.2	9.0	47.8	1.7	.40	1.90	4.87	13.50	41.8	85.7	27.6	32.2	14.2	313	8.80
4	6.8	35.1	7.9	57.0	2.4	.50	3.90	4.82	14.30	43.9	91.1	29.6	32.5	12.9	211	9.60
5	8.3	46.0	7.9	46.1	3.8	.70	3.80	3.70	14.00	42.8	115.7	37.9	32.8	13.7	276	8.50
7	9.6	72.8	8.5	18.7	7.0	.80	1.70	4.18	11.80	38.4	92.0	28.3	30.8	13.7	195	9.80
8	4.9	32.0	10.2	57.8	1.6	.50	1.80	4.78	13.50	42.3	88.4	28.2	31.9	13.5	237	9.60
9	5.4	31.8	6.8	61.4	1.7	.40	2.80	5.51	15.90	49.8	90.4	28.9	32.0	13.4	217	10.60
10	4.3	51.5	6.6	41.9	2.2	.30	3.30	5.26	14.80	45.8	87.1	28.1	32.3	16.8	325	7.40
13	4.7	52.1	8.2	39.7	2.4	.40	1.80	4.68	13.90	43.7	93.5	29.7	31.8	13.8	271	10.10
14	6.0	47.6	7.0	45.6	2.8	.40	1.90	3.35	12.80	25.3	76.0	38.2	50.6	-	-	-
15	5.0	38.9	8.7	52.4	1.9	.40	2.70	4.32	13.60	41.6	96.2	31.5	32.7	13.5	216	8.90
17	5.5	53.9	4.2	41.9	3.0	.20	2.60	4.80	12.80	40.1	83.5	26.6	31.6	14.3	237	9.90
19	5.8	36.4	3.8	39.8	3.3	.20	2.30	3.56	9.40	29.9	83.9	26.5	31.6	14.0	103	8.70
21	7.6	30.9	8.0	61.1	2.3	.60	2.30	3.76	11.00	34.6	92.0	29.3	31.8	13.9	396	8.70
22	4.4	43.7	10.1	46.2	1.9	.40	4.60	3.59	10.20	32.2	89.7	28.5	31.7	10.7	201	14.00
25	5.1	39.9	11.2	46.7	2.0	.60	2.00	5.05	10.60	34.5	68.2	21.0	30.9	20.9	257	9.20
27	6.5	49.2	4.1	40.4	3.2	.30	2.50	5.50	14.40	44.8	81.5	26.2	32.2	13.8	322	8.90
28	4.8	32.5	7.1	51.9	2.5	.30	3.00	4.46	10.60	34.9	78.3	23.8	30.4	15.7	348	8.70
29	9.0	40.0	8.1	33.5	3.6	.70	1.90	5.02	13.70	42.4	84.4	27.3	32.3	14.9	203	8.20
30	3.1	57.6	8.9	51.8	1.8	.30	4.70	5.57	16.20	50.0	89.7	29.1	32.5	14.5	236	9.20
33	6.1	35.4	12.8	49.9	2.2	.80	1.00	3.96	10.50	33.8	85.2	26.6	31.2	14.2	393	7.50
34	7.9	45.9	4.2	62.5	3.6	.30	3.20	4.97	13.10	42.0	84.5	26.5	31.3	15.1	246	10.90
36	4.9	26.2	11.3	56.9	1.3	.60	3.90	5.16	14.20	45.3	87.8	27.5	31.3	13.4	271	9.80
37	5.0	29.1	14.0	52.4	2.1	.50	3.10	2.13	8.90	26.6	125.0	41.6	33.3	18.4	175	8.70
38	3.7	37.0	10.6	45.3	1.4	.40	2.40	4.22	14.20	43.0	101.9	33.6	33.0	13.2	222	9.40
40	4.6	51.1	3.6	66.9	2.4	.20	1.90	4.05	9.80	31.5	77.8	24.1	31.1	18.0	308	11.30
41	5.2	24.9	8.2	41.0	1.3	.40	2.10	4.49	11.10	35.6	79.1	24.7	31.2	16.3	203	9.90
42	4.3	47.6	11.4	44.0	2.0	.50	3.50	4.71	14.70	45.7	97.0	31.2	32.2	15.6	204	9.40
46	11.1	45.9	10.1	43.5	5.1	1.10	1.80	4.31	9.90	31.5	73.2	22.9	31.3	18.3	449	10.00
47	7.8	45.2	11.3	43.5	3.5	.90	4.90	4.14	11.50	36.2	87.4	27.8	31.8	16.2	331	8.90
48	6.9	54.1	13.2	32.7	3.7	.90	3.40	4.09	12.40	39.3	96.2	30.3	31.4	20.5	251	7.30
54	3.3	41.6	12.2	46.2	1.4	.40	2.30	4.49	11.70	37.7	84.1	26.1	31.0	18.0	213	10.60
56	4.7	48.7	13.3	38.0	2.3	.60	1.50	4.18	11.10	37.5	89.8	26.6	29.7	14.0	211	10.80
57	4.0	24.7	9.0	66.2	1.0	.40	1.80	4.94	13.10	41.1	83.3	26.5	31.8	15.4	193	8.20
59	4.3	43.4	7.5	49.1	1.9	.30	2.70	4.17	11.60	37.4	89.8	27.8	31.0	16.8	302	9.60

Table 13B: HAEMATOLOGY-POST INTERVENTION DATA (3 MONTHS)

Patient IDNO	WBC	LY%	MO%	GR%	LY	MO	GR	RBC	Hgb	Hct	MCV	MCH	MCHC	RDW	HL	MPV
1	3.6	44.1	3.3	52.6	1.6	0.1	1.9	4.62	12.1	38.1	82.4	26.2	31.8	14.8	309	9.0
4	4.9	33.0	11.6	55.4	1.6	0.6	2.7	4.55	13.3	39.0	85.7	29.2	34.1	13.0	141	10.4
5	5.7	28.8	3.2	68.0	1.6	0.2	3.9	3.96	15.1	45.4	114.7	38.1	33.2	13.2	238	9.2
7	5.8	65.5	8.7	25.8	3.8	0.5	1.5	4.09	11.5	35.4	86.4	28.1	32.6	12.8	177	8.6
8	5.4	33.7	10.5	55.8	1.8	0.6	3.0	5.11	13.8	41.4	80.9	27.1	33.5	13.5	215	9.7
9	4.6	33.1	4.6	62.3	1.5	0.2	2.9	4.73	13.7	41.1	87.0	29.0	33.4	14.2	130	9.6
10	4.6	21.9	6.4	71.7	1.0	0.3	3.3	5.24	14.0	42.2	80.6	26.7	31.1	15.1	159	8.4
13	4.5	47.5	1.4	51.1	2.1	0.1	2.3	4.48	13.0	39.4	87.8	28.9	32.9	13.8	240	9.9
14	6.6	41.7	12.3	46.0	2.8	0.8	3.0	4.82	13.1	40.3	83.7	27.2	32.5	14.6	229	9.7
15	6.2	36.8	6.2	57.0	2.3	0.7	3.2	4.78	14.6	42.8	90.0	30.6	34.0	13.1	154	9.9
17	3.9	41.8	5.7	57.5	1.6	0.2	2.0	4.90	12.8	39.7	81.0	26.2	32.3	13.9	168	10.6
19	7.2	49.1	6.0	44.9	3.5	0.4	3.2	5.14	13.8	42.1	81.9	26.9	32.8	12.9	213	8.3
21	5.8	42.5	5.1	52.4	2.5	0.3	3.0	3.66	10.4	31.6	86.3	28.5	33.0	16.2	403	8.4
22	5.8	26.4	4.2	69.4	1.5	0.3	4.0	372	10.4	31.6	84.9	28.0	32.9	14.4	178	10.8
25	6.0	38.7	4.8	56.5	2.3	0.3	3.4	5.16	10.8	24.4	66.6	20.9	31.4	18.9	196	10.7
27	5.7	53.3	33.2	13.5	3.0	1.9	0.8	5.81	14.0	43.7	75.3	24.1	32.0	12.6	317	9.3
28	4.6	41.9	8.0	50.1	1.9	0.4	2.3	4.64	9.7	33.6	72.6	20.8	28.7	15.3	394	7.6
29	5.4	40.5	0.9	58.6	2.2	-	3.2	4.96	13.4	40.3	81.2	27.1	33.4	13.4	177	9.3
30	3.3	47.3	3.4	49.3	1.6	0.1	1.6	5.34	15.3	45.0	84.3	28.5	33.9	13.8	232	9.2
33	5.1	31.4	10.5	58.1	1.6	0.5	3.0	3.82	9.5	30.1	78.8	24.9	31.6	17.5	316	7.8
34	3.7	59.3	6.2	34.5	2.2	0.2	1.3	4.44	11.9	36.8	82.9	26.8	32.3	13.4	198	10.8
36	3.7	23.7	6.8	69.5	0.9	0.3	2.6	4.99	13.4	42.7	85.5	26.8	31.3	13.7	249	10.1
37	4.4	25.0	6.0	69.0	1.1	0.3	3.0	2.71	9.8	28.8	106.4	36.1	33.9	18.4	160	8.3
38	4.7	29.7	4.0	66.3	1.4	0.2	3.1	4.5	14.0	43.0	95.6	31.1	32.5	12.2	246	9.2
40	5.2	50.6	7.8	41.2	2.6	0.4	2.2	4.33	10.6	32.9	76.0	24.6	32.3	19.9	263	12.0
41	5.0	31.5	1.9	66.6	1.6	0.1	3.3	4.96	12.2	37.6	75.7	24.6	32.5	14.3	244	9.9
42	3.4	45.9	16.9	37.2	1.6	0.6	1.3	4.58	14.4	42.7	93.2	31.4	33.7	14.6	182	9.5
46	11.6	58.7	14.2	27.1	6.8	1.6	3.1	4.37	9.8	30.4	69.6	22.4	32.2	19.7	232	12.2
47	7.7	36.2	2.1	61.7	2.8	0.2	4.8	4.22	11.4	34.2	81.8	27.1	33.4	13.9	252	10.5
48	4.3	52.5	15.2	32.3	2.3	0.7	1.4	5.03	15.0	44.1	87.6	29.8	34.0	13.3	130	9.0
54	4.1	41.3	17.6	41.1	1.7	0.7	1.7	4.53	11.6	35.2	77.9	25.6	32.9	17.7	161	12.6
56	4.1	46.8	15.5	37.7	1.9	0.6	1.5	4.16	11.0	33.7	81.0	26.5	32.7	15.0	150	11.9
57	4.6	34.9	5.2	59.9	1.6	0.9	2.8	5.60	14.1	44.2	79.0	25.3	32.0	16.1	224	9.2
59	3.9	55.8	16.4	27.8	2.2	0.6	1.1	4.97	13.5	41.4	83.2	27.1	32.6	18.1	301	9.3

Table 13C: HAEMATOLOGY-POST INTERVENTION DATA (12 MONTHS)

Patient IDNO	WBC	LY%	MO%	GR%	LY	MO	GR	RBC	Hgb	Hct	MCV	MCH	MCHC	RDW	PLT	MPV
1	3.5	59.0	2.8	38.1	2.4	0.1	1.0	4.34	13.2	34.8	80.4	30.4	32.8	14.9	328	8.8
4	5.6	44.8	10.0	45.2	2.4	0.6	2.5	4.32	13.7	39.6	83.1	28.6	31.9	12.7	321	8.1
5	5.3	43.1	7.9	49.0	2.3	0.4	2.6	3.91	15.2	44.7	108.4	34.6	36.1	12.2	343	8.8
7	6.9	70.8	5.4	23.8	5.0	0.4	1.5	3.42	10.2	29.3	85.6	30.1	31.9	12.6	318	7.9
8	4.9	45.6	8.3	47.1	2.2	0.4	2.3	5.07	13.7	40.7	80.3	29.9	32.6	12.6	264	9.3
9	6.1	45.0	8.6	46.4	2.6	0.9	2.6	3.64	11.4	32.1	88.3	31.4	35.6	13.8	265	8.5
10	5.2	39.0	8.4	52.6	1.9	0.7	2.6	5.14	13.4	41.3	81.2	30.0	34.3	13.5	364	7.3
13	4.9	69.8	4.1	26.1	3.5	0.2	1.2	4.20	12.6	34.8	82.9	29.9	36.0	13.5	334	8.2
14	4.7	65.5	3.3	31.2	3.1	0.2	1.5	4.70	13.1	39.9	84.9	31.5	33.1	14.6	169	8.0
15	6.1	43.2	9.0	57.8	2.5	0.5	3.1	4.44	14.3	39.0	87.7	32.1	36.6	12.8	253	7.6
17	4.9	53.5	4.2	42.3	2.6	0.2	2.1	4.60	12.1	36.0	78.3	26.2	33.5	14.6	302	9.0
19	7.4	31.8	5.4	62.8	2.4	0.4	4.6	4.31	12.1	34.9	81.1	28.1	34.7	12.9	225	8.5
21	5.2	46.1	6.5	47.4	2.4	0.3	2.5	5.25	16.1	45.2	86.1	30.6	35.6	14.5	358	7.3
22	4.7	59.5	5.7	34.8	2.7	0.2	1.8	3.52	10.9	29.8	84.7	28.1	29.4	13.6	213	9.1
25	4.2	49.8	5.6	44.6	2.1	0.3	1.8	4.95	11.0	32.1	66.0	22.6	30.9	16.2	209	8.6
27	7.5	50.8	8.1	41.1	3.6	0.7	3.4	5.75	13.5	42.7	78.3	26.7	31.9	13.9	373	8.9
28	6.3	61.7	7.4	30.9	3.9	0.3	2.1	4.70	12.2	35.3	75.2	25.9	30.3	14.0	290	7.6
29	5.3	39.6	5.8	54.6	2.2	0.3	2.8	4.91	14.6	39.2	79.9	29.8	35.1	13.8	246	8.2
30																
33	8.4	27.5	11.6	60.9	2.2	0.8	5.0	3.73	10.4	29.7	79.7	27.8	34.9	20.3	402	7.3
34	7.2	48.1	5.6	53.7	2.6	0.4	4.2	5.00	14.4	44.7	81.4	28.9	33.1	12.6	260	9.4
36	3.3	41.3	6.7	52.0	1.4	0.3	1.6	4.57	13.7	39.2	85.3	30.0	35.0	12.6	245	9.1
37	5.2	38.5	9.3	52.2	2.0	0.6	2.6	3.63	14.4	40.2	110.6	29.6	33.1	15.2	171	8.2
38	3.1	54.0	4.3	41.7	1.7	0.1	1.3	5.83	14.1	46.1	92.9	34.1	36.7	12.4	303	8.0
40	5.9	49.0	9.9	51.1	2.5	0.7	2.7	4.37	9.9	29.1	76.5	22.6	31.9	16.4	403	10.9
41	3.1	35.2	6.1	58.7	1.2	0.2	1.7	4.55	12.1	35.1	77.0	26.7	34.6	14.3	221	9.7
42	5.7	40.2	6.8	53.0	2.5	0.4	2.8	5.10	15.2	46.2	90.6	29.0	29.6	12.8	171	9.2
46	9.2	61.9	4.3	33.8	5.7	0.4	3.1	4.38	10.7	31.2	71.2	24.3	34.2	17.5	232	8.2
47	6.4	41.6	9.6	48.8	2.8	0.5	3.1	4.30	12.4	35.6	82.9	28.9	34.9	8.1	312	14.1
48	5.6	48.2	5.0	46.8	2.7	0.3	2.6	5.28	17.2	47.7	90.4	32.6	36.1	12.4	186	7.9
54	4.6	28.2	6.3	66.5	1.4	0.2	3.0	4.36	12.7	35.1	80.5	29.1	30.9	14.9	308	10.1
56	5.2	50.9	7.2	41.9	2.6	0.4	2.2	4.08	12.5	32.6	80.0	25.5	33.0	14.2	320	9.9
57	5.1	34.7	4.3	61.0	1.8	0.2	3.1	5.45	15.6	41.7	76.4	29.3	31.4	16.1	273	8.5
59	5.5	47.2	8.1	44.7	2.6	0.4	2.5	5.15	14.1	44.6	86.9	31.0	33.1	15.8	340	8.8

Table 13D: HAEMATOLOGY-POST INTERVENTION DATA (18 MONTHS)

Patient IDNO	WBC	LY%	MO%	GR%	LY	MO	GR	RBC	Hgb	Hct	MCV	MCH	MCHC	RDW	PLT	MPV
1	3.5	59.1	8.9	32.0	2.1	0.3	1.1	4.56	12.6	49.7	87.0	27.7	31.8	16.8	553	7.5
4	5.7	29.4	16.8	53.8	1.7	1.0	3.1	4.80	13.1	42.8	89.2	27.2	30.5	15.4	323	8.2
5	5.3	43.1	7.9	46.0	2.3	0.4	2.6	3.91	15.2	44.7	108.2	34.6	36.1	12.2	343	9.0
7	6.8	62.7	8.0	29.3	4.3	0.5	2.0	3.58	9.6	31.0	91.6	28.4	31.0	14.2	319	7.2
8	5.5	36.6	6.2	57.2	2.0	0.3	2.2	5.48	14.3	48.0	87.7	26.2	29.8	14.5	400	8.0
9	6.2	39.7	3.7	57.3	2.4	0.2	3.6	4.52	12.9	39.1	86.6	28.6	33.0	14.7	328	8.1
10	3.3	52.9	4.6	42.5	1.7	0.2	1.4	4.84	13.5	41.7	86.1	27.9	32.4	21.9	400	7.5
13	4.0	49.4	4.0	46.6	2.0	0.2	1.9	4.51	12.4	39.0	88.3	27.5	31.1	17.9	316	8.1
14	7.7	32.3	7.8	59.9	2.5	0.6	4.6	4.76	14.7	46.6	97.9	30.9	31.6	13.2	201	8.0
15	5.4	35.4	17.6	47.0	1.9	1.0	2.5	4.34	13.7	42.5	98.0	31.5	32.2	15.9	426	7.0
17	4.7	52.6	8.6	38.0	2.5	0.4	1.8	4.90	12.7	42.4	86.6	26.0	30.0	14.6	299	7.8
19	4.3	55.9	3.7	40.4	2.4	0.2	1.7	4.42	11.6	38.0	85.9	26.3	30.6	14.1	273	7.3
21	5.8	34.7	4.9	60.4	2.0	0.3	3.5	3.37	10.8	31.5	93.5	32.2	34.4	15.5	571	7.7
22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	6.5	44.0	18.0	38.0	2.9	1.2	2.5	5.43	11.3	38.7	71.2	20.7	29.1	18.8	253	8.0
27	6.3	51.9	5.7	42.4	3.3	0.4	2.7	5.53	14.0	43.7	79.0	25.4	32.1	13.8	435	7.3
28	5.0	45.2	5.8	49.0	2.3	0.3	2.5	4.65	12.0	38.3	82.4	25.7	31.2	14.9	280	7.9
29	3.6	41.6	1.1	57.3	1.5	0.1	2.0	4.80	13.5	40.6	84.6	28.1	33.2	13.9	283	7.1
30	3.7	43.0	1.5	59.4	2.3	0.2	2.0	4.90	14.0	47.2	89.0	29.3	35.7	15.4	302	9.3
33	5.8	45.5	6.7	47.8	2.6	0.4	2.8	4.04	10.5	33.5	83.1	26.1	31.4	17.4	361	7.9
34	6.9	57.4	1.3	41.3	4.0	0.1	2.8	4.76	12.9	41.3	86.9	27.2	31.3	16.1	188	8.5
36	4.0	13.5	6.3	80.2	0.5	0.3	3.2	3.81	10.4	33.6	88.2	27.4	31.1	14.7	242	8.7
37	4.0	46.4	9.2	44.4	1.9	0.4	1.8	3.00	11.1	33.4	111.6	37.2	33.3	18.2	217	7.6
38	3.8	32.8	8.5	58.7	1.2	0.3	2.2	4.30	13.6	42.7	99.3	31.5	31.8	14.5	314	8.0
40	11.0	28.6	21.4	50.0	3.1	2.4	5.5	4.12	8.6	30.7	74.6	20.9	28.0	19.1	492	9.2
41	4.7	25.5	19.0	55.5	1.2	0.9	2.6	4.65	11.6	39.3	84.4	25.0	29.7	16.1	324	8.2
42	3.4	44.8	11.6	42.6	1.5	0.4	1.5	4.80	15.0	45.9	95.8	31.2	32.6	15.8	300	9.1
46	9.2	61.9	4.3	33.8	5.7	0.4	3.1	4.38	10.7	31.2	71.2	24.3	34.2	17.5	232	9.5
47	6.4	41.6	9.6	48.8	2.8	0.5	3.1	4.30	12.4	35.6	82.9	28.9	34.9	8.1	312	10.1
48	5.6	48.3	5.1	46.9	2.9	0.5	2.6	5.28	11.2	47.7	90.4	32.6	36.1	12.4	186	8.3
54	5.0	23.6	2.0	74.4	1.2	0.1	3.7	4.14	11.2	36.2	87.4	27.0	30.9	15.2	271	8.2
56	4.9	57.2	3.6	39.2	2.8	0.2	1.9	4.26	11.2	37.8	88.8	26.3	29.6	15.6	281	8.7
57	5.5	40.8	8.2	51.0	2.2	0.5	2.8	5.51	14.0	43.2	78.4	25.5	32.5	18.0	248	8.0
59	5.4	49.7	8.3	42.0	2.7	0.4	2.3	4.54	12.5	41.4	91.3	27.6	30.2	15.9	356	8.2

Table 13E: HAEMATOLOGY-POST INTERVENTION DATA (30 MONTHS)

Patient IDNO	WBC	LY%	MO%	GR%	LY	MO	GR	RBC	Hgb	Hct	MCV	MCH	MCHC	RDW	PLT	MPV
1	4.9	36	11	-	-	-	-	3.8	12.1	38.0	80.8	25.7	-	-	214	-
4	7.5	21	3					4.5	13.1	39.4	87.1	28.9			293	
5	4.9	49	5					4.0	14.6	44.2	110.7	36.5			131	
7	4.7	66	16					3.6	12.0	36.0	101.4	33.8			270	
8	4.6	33	13					5.0	13.4	40.2	79.7	26.5			203	
9	5.8	38	15					4.6	13.1	38.5	84.1	28.6			253	
10	Died	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	5.1	48	3					4.5	11.3	33.4	75.1	25.4			264	
14	5.4	44	10					4.4	12.1	35.8	80.5	27.3			119	
15	6.1	39	8					4.9	15.1	43.3	88.1	30.7			182	
17	4.9	55	8					5.05	13.0	41.7	82.6	25.8			231	
19	4.6	28	8					4.6	12.6	38.9	79.1	25.5			202	
21	5.8	24	7					3.2	10.4	29.3	91.3	32.3			397	
22	Died															
25	7.9	39	8					5.4	11.3	36.3	67.7	21.0			340	
27	6.0	57	8					5.5	13.2	40.9	74.6	24.1			339	
28	5.2	50	6					4.8	11.7	37.0	77.2	26.4			208	
29	4.2	41	10					4.6	12.6	37.8	82.5	27.6			165	
30	Died															
33	4.6	24	10					4.3	11.4	34.5	79.9	26.3			232	
34	7.1	62	7					5.1	13.5	41.1	80.9	26.5			237	
36	Died															
37	3.5	37	4					3.3	12.3	37.3	113.7	37.5			397	
38	4.5	34	4					4.1	12.5	37.7	93.1	30.8			186	
40	6.0	39	10					4.6	9.3	30.3	65.8	20.2			440	
41	2.9	28	10					4.8	11.4	36.2	75.7	23.8			204	
42	3.1	43	10					5.1	15.9	47.0	91.6	30.9			146	
46	Died															
47	6.6	39	10					4.6	11.6	6.7	80.0	25.3			261	
48	4.5	35	8					5.1	15.8	46.1	90.2	30.9			151	
54	3.1	45	10					4.5	12.3	37.1	82.7	27.5			193	
56	4.9	20	5					3.5	7.8	25.3	72.3	22.3			331	
57	4.9	24	8					6.0	14.5	43.6	77.6	20.1			218	
59	4.8	55	7					4.8	13.6	39.9	83.8	28.6			230	

Table 14A: HIV/AIDS VIUSID BIOCHEMISTRY BASELINE DATA

Patient ID NO	Bilirubin	AST	ALT	ALPh	BUN	S. Creatinine	T. Protein	Albumin	Uric Acid	Glucose
1	10.4	10.0	43.0	91.0	13.1	123.0	79.0	34	328	3.5
3	10.3	10.0	13.0	127.0	7.2	106.0	70.0	35	473	3.8
4	13.2	32.0	14.0	132.0	3.4	108.0	77.0	38	289	4.7
5	14.5	34.0	23.0	69.0	4.0	102.0	690	36	281	3.4
6	8.5	11.0	12.0	127.0	3.5	110.0	75.0	42	307	4.1
7	15.4	37.0	25.0	68.0	7.2	108.0	80.0	37	359	3.6
8	12.6	35.0	24.0	109.0	3.7	107.0	63.0	40	433	4.2
9	14.2	38.0	24.0	110.0	4.1	105.0	70.0	47	399	3.6
10	18.2	49.0	41.0	129.0	5.0	105.0	69.0	38	487	4.1
13	12.9	34.0	3.0	64.0	3.8	99.0	67.0	46	414	3.8
14	8.6	28.0	20.0	102.0	3.0	118.0	69.0	30	397	4.8
15	7.8	29.0	24.0	121.0	2.3	121.0	63.0	31	291	3.0
17	11.4	34.0	25.0	85.0	3.4	110.0	74.0	42	388	3.8
19	10.8	27.0	17.0	93.0	5.8	105.0	89.0	39	359	4.7
21	10.9	28.0	10.0	62.0	3.5	107.0	86.0	44	365	4.8
22	10.3	51.0	4.0	73.0	6.7	128.0	80.0	35	377	4.0
25	13.2	18.0	4.0	104.0	2.7	108.0	81.0	43	427	5.3
27	10.0	28.0	14.0	74.0	3.8	106.0	74.0	32	263	4.4
28	10.4	36.0	16.0	82.0	2.8	109.0	72.0	40	369	4.5
29	11.1	55.0	26.0	67.0	2.6	105.0	74.0	42	354	4.3
30	19.0	54.0	42.0	81.0	3.5	104.0	83.0	46	467	3.8
33	9.6	40.0	4.0	101.0	4.3	105.0	75	36	469	4.0
34	14.0	33.0	10.0	73.0	2.6	108.0	86.0	36	369	4.1
36	10.4	23.0	21.0	120.0	2.6	108.0	83.0	46	355	4.2
37	11.6	27.0	10.0	100.0	7.2	133.0	78.0	35	504	6.1
38	9.4	43.0	10.0	54.0	4.5	86.0	75.0	37	312	3.6
40	6.4	9.0	8.0	101.0	3.1	106.0	86.0	35	372	4.1
41	11.3	31.0	18.0	109.0	2.6	106.0	87.0	30	462	6.3
42	10.4	40.0	20.0	84.0	2.6	101.0	74.0	37	399	3.6
46	8.9	22.0	4.0	101.0	5.1	123.0	100.0	35	338	6.5
47	18.3	45.0	35.0	132.0	2.4	105.0	79.0	38	353	3.5
48	13.1	10.0	23.0	19.0	2.5	116.0	87.0	32	377	3.4
54	9.8	66.0	15.0	83.0	2.4	101.0	79.0	39	420	3.8
56	13.4	29.0	20.0	78.0	3.0	107.0	80.0	38	389	4.0
57	16.4	47.0	30.0	115.0	6.9	110.0	76.0	45	389	6.6
59	8.9	43.0	14.0	78.0	4.6	109.0	74.0	41	256	4.2

KEY: AST-Aspartate Transminase
 ALP-Alanine Transaminase
 Alph-Alkaline Phosphatase BUN-Blood Urea Nitrogen

Table 14B: HIV/AIDS VIUSID BIOCHEMISTRY POST-INTERVENTION DATA (3 MONTHS)

Patient ID NO	Bilirubin	AST	ALT	ALP	BUN	S. Creatinine	T. Protein	Albumin	Uric Acid	Glucose
1	8.7	43	17	119	2.7	91	78	34	443	4.8
4	10.3	29	16	119	3.7	95	78	41	358	5.0
5	11.3	34	6	89	3.8	105	87	51	342	4.8
7	7.3	43	9	101	2.8	97	83	36	469	4.3
8	8.4	7	20	98	3.3	119	77	40	560	4.1
9	11.2	39	11	87	2.7	119	76	40	453	6.5
10	9.9	25	13	78	2.8	96	72	37	373	5.3
13	8.6	22	17	90	3.4	113	84	45	433	5.7
14	10.4	30	4	96	2.8	116	84	34	334	5.3
15	9.6	24	10	109	2.7	109	69	40	531	3.8
17	9.9	7	12	67	3.5	124	92	51	430	7.1
19	10.6	23	4	84	3.6	104	80	40	362	5.1
21	10.4	14	13	96	7.8	124	80	37	719	4.8
22	11.2	18	7	78	2.8	103	77	27	514	5.7
25	10.4	34	7	83	2.3	101	72	39	461	7.2
27	8.7	34	7	94	3.5	105	65	33	443	4.8
28	10.2	25	14	93	3.6	131	86	48	561	5.8
29	9.9	25	9	100	3.7	99	73	31	455	3.9
30	9.6	14	10	96	3.9	104	75	42	554	9.4
33	6.3	8	11	88	2.9	105	84	45	484	9.8
34	8.3	45	12	90	3.9	97	75	44	530	4.0
36	11.0	47	18	79	5.1	117	73	40	553	3.4
37	10.4	9	4	121	2.8	108	68	30	605	5.0
38	9.9	18	11	86	3.8	110	80	37	605	4.6
40	11.3	29	8	108	3.4	101	70	38	397	5.2
41	11.3	20	8	113	5.0	121	89	36	453	4.9
42	9.6	50	7	109	3.2	98	74	35	640	4.0
46	10.0	48	7	88	6.4	134	100	31	585	8.0
47	8.6	36	11	96	2.9	115	72	31	568	4.3
48	9.2	65	13	124	3.6	105	85	37	488	4.9
54	12.3	27	17	87	2.8	104	83	34	550	3.9
56	9.1	42	13	110	2.9	101	63	46	404	5.2
57	8.7	58	34	100	7.0	145	131	58	572	10.5
59	10.9	14	12	113	4.9	115	63	39	490	6.3

NORMAL RANGES FOR GIVEN PARAMETERS (BIOCHEMISTRY)

	NORMAL REFERENCE RANGES	
T.BIL – (Bilirubin)	1.71 – 20.5	∞mols/l
AST (Aspartate Transaminase)	0 – 33	∞l
ALT (Alanine Transaminase)	0 – 43	∞/l
ALP (Altraline Phosphatase)	34 – 114	∞/l
T.Prot. (Total Protein)	60 – 80	g/l
Alb (Albumin)	32 – 52	g/l
Nat (Sodium)	130 – 150	∞mo∞
AT (Potassium)	3.0 – 5.2	∞mo∞
BUN (Urea)	-	-
Creat. (Creatinine)	60 – 130	∞mo∞
U/A (Uric Acid)	149 – 458	∞mo∞
Gluc. (Glucose)	3.8 – 6.8	∞mo∞

Table 14C: HIV/AIDS VIUSID BIOCHEMISTRY BASELINE DATA (12 MONTHS)

Patient ID NO	Bilirubin	AST	ALT	ALPh	BUN	S. Creatinine	T. Protein	Albumin	Uric Acid	Glucose
1	10.4	35	17	75	3.6	117	92	31	328	3.5
4	16.4	36	6	80	3.4	104	78	36	289	4.7
5	10.4	34	17	76	3.3	110	76	34	281	3.4
7	8.6	44	14	65	6.3	133	83	44	359	3.6
8	10.4	36	12	70	3.1	109	74	36	433	4.2
9	11.6	22	13	70	3.0	111	73	22	399	3.6
10	9.7	35	34	131	2.6	106	79	35	487	4.1
13	7.6	31	15	96	3.2	96	76	31	414	3.8
14	10.4	40	20	88	3.0	103	73	40	397	4.8
15	11.6	29	26	65	3.3	101	68	29	291	3.0
17	13.4	29	14	93	3.6	102	87	29	388	3.8
19	10.6	31	11	90	3.2	100	77	31	359	4.7
21	11.6	34	12	96	6.3	104	87	34	365	4.8
22	9.3	44	15	80	3.3	106	88	44	377	4.0
25	14.3	39	15	91	3.3	89	70	39	427	5.3
27	10.4	30	15	93	4.0	102	77	30	263	4.4
28	4.3	20	9	80	3.4	103	77	20	369	4.5
29	7.6	19	12	68	3.1	104	88	19	354	4.3
30	19.0	54.0	42.0	81.0	3.5	104.0	83.0	46	467	3.8
33	8.6	16	11	74	3.3	89	65	39	469	4.0
34	11.0	16	9	68	3.2	100	75	30	369	4.1
36	13.0	30	22	98	4.0	107	78	28	355	4.2
37	9.3	28	16	124	4.2	101	73	41	504	6.1
38	7.8	41	18	61	3.1	104	79	43	312	3.6
40	11.0	43	22	90	2.4	97	85	26	372	4.1
41	13.4	26	11	72	3.6	106	92	32	462	6.3
42	16.3	35	16	83	3.3	117	97	49	399	3.6
46	18.4	49	15	127	3.4	103	88	30	338	6.5
47	12.3	30	15	82	3.6	99	78	17	353	3.5
48	6.9	37	14	72	3.3	110	86	46	377	3.4
54	7.3	46	60	101	3.8	103	89	49	420	3.8
56	9.0	49	10	80	3.8	100	90	29	389	4.0
57	10.1	29	29	81	3.2	103	83	37	389	6.6
59	11.1	37	19	68	3.3	104	76	30	256	4.2

KEY:

AST-Aspartate Transminase ALP-Alanine Transaminase, ALPh-Alkaline Phosphatase, BUN-Blood Urea Nitrogen

Table 14D: HIV/AIDS VIUSID BIOCHEMISTRY POST-INTERVENTION DATA (18 MONTHS)

Patient ID NO	Bilirubin	AST	ALT	ALP	BUN	S. Creatinine	T. Protein	Albumin	Uric Acid	Glucose
1	10.4	38	28	62	4.6	123	73	38		4.8
4	16.1	64	31	78	3.2	103	78	38		4.6
5	10.4	34	17	80	3.4	104	78	36		4.7
7	10.4	26	26	64	7.9	152	99	41		4.49
8	17.2	72	61	99	3.7	104	87	48		3.72
9	11.4	41	35	96	4.2	129	96	42		5.47
10	11.6	56	36	71	3.6	102	80	49		4.69
13	13.4	37	16	81	3.1	98	90	51		4.26
14	19.8	93	33	67	4.1	102	91	43		4.31
15	19.3	101	47	63	3.9	102	83	48		4.63
17	10.3	109	4	90	4.1	99	93	51		4.36
19	10.6	31	11	90	3.2	100	77	31		4.7
21	11.3	86	17	76	8.2	144	99	34		5.06
22	-	-	-	-	-	-	-	-		Died
25	16.1	17	16	97	3.9	112	88	46		4.22
27	9.2	63	16	85	3.6	100	96	50		4.56
28	12.2	28	13	80	4.0	133	94	45		4.53
29	13.2	60	18	83	4.0	108	96	49		4.15
30	19.0	54	42	81	3.5	104	83	46		3.8
33	10.3	76	16	81	3.6	97	97	39		4.62
34	9.2	36	27	74	3.9	88	89	45		4.34
36	10.4	56	15	67	3.6	104	86	46		4.33
37	14.0	35	32	60	4.8	99	81	40		4.48
38	13.6	33	24	55	4.0	100	90	54		5.53
40	11.2	43	12	60	3.9	96	78	41		5.02
41	12.7	51	10	85	4.2	102	83	42		4.67
42	13.1	59	24	65	4.0	100	62	30		4.02
46	14.3	29	35	59	4.1	106	101	42		5.51
47	12.3	30	15	82	3.6	99	78	17		3.50
48	6.9	37	14	72	3.3	110	86	46		3.40
54	10.4	36	15	74	3.3	83	89	41		5.04
56	7.3	36	18	68	4.3	101	83	41		4.47
57	8.3	28	15	73	4.0	96	78	44		8.36
59	10.3	25	16	81	3.9	109	76	41		4.17

Table 14E: HIV/AIDS VIUSID BIOCHEMISTRY POST-INTERVENTION DATA (30 MONTHS)

Patient ID NO	Bilirubin	AST	ALT	ALP	BUN	S. Creatinine	T. Protein	Albumin	Retino l (mcm ol/L)	Glucose
1	7.4	30	9	102	3.5	110	76.4	40.7	0.44	6.54
4	8.6	33	12	98	4.2	106	70.8	35.9	0.73	5.56
5	Little sample-	-	-	-	-	-	-	-		-
7	9.4	66	12	99	4.3	124	77.9	41.7	0.78	7.74
8	10.3	18	23	106	4.0	114	75.8	49.3	1.10	10.40
9	13.4	49	14	78	3.8	109	89.6	44.4	0.68	10.46
10	Dead	-	-	-	-	-	-	-	-	-
13	14.6	30	6	93	4.2	98	76.4	51.5	0.94	10.52
14	9.4	40	17	104	4.6	128	82.3	34.9	0.60	8.44
15	10.6	52	40	98	4.0	99	75.2	42.1	0.71	6.83
17	8.3	42	21	90	5.0	106	79.3	40.0	0.63	3.72
19	9.4	36	12	102	4.8	99	70.4	31.5	0.96	11.64
21	10.6	33	15	99	3.6	109	74.5	28.7	0.41	3.99
22	Dead	-	-	-	-	-	-	-	-	-
25	7.6	29	17	74	3.6	120	76.2	36.8	0.62	7.9
27	7.7	28	08	89	2.4	89	77.8	42.7	0.44	5.82
28	8.3	47	36	79	3.8	99	76.5	46.3	0.63	3.61
29	9.4	43	7	83	4.1	130	80.3	46.4	0.49	3.66
30	Dead	-	-	-	-	-	-	-	-	-
33	11.6	49	4	96	4.2	103	80.4	45.2	0.64	4.22
34	8.4	39	32	101	3.9	101	90.6	48.2	1.41	2.93
36	Dead	-	-	-	-	-	-	-	-	-
37	9.3	48	18	99	5.0	122	90.6	50.8	0.78	4.20
38	10.0	40	24	94	4.2	99	79.3	42.1	0.72	2.84
40	11.6	33	10	101	3.6	108	80.4	36.2	0.61	4.31
41	13.4	32	19	83	3.4	93	89.3	35.2	0.77	4.62
42	14.4	56	26	88	3.8	123	76.4	50.3	1.49	4.80
46	Dead	-	-	-	-	-	-	-	-	-
47	13.4	47	21	96	3.9	106	76.9	37.8	0.57	2.41
48	12.6	86	11	99	4.2	114	80.2	46.8	1.01	5.23
54	13.3	43	61	101	4.6	109	73.2	42.4	1.08	5.26
56	10.0	33	38	102	4.0	106	89.6	54.2	0.35	3.43
57	11.1	41	26	100	3.9	101	75.4	49.3	1.19	7.59
59	12.3	35	19	96	3.2	102	76.3	45.4	1.01	5.81

TABLE 15: OVERALL IMMUNOLOGY/VIROLOGY RESULTS AT 18 MONTHS

PARAMETER	BASELINE			18 MONTHS		
	MEAN	MEDIAN	STD MEAN ERROR	MEAN	MEDIAN	STD MEAN ERROR
CD4	445	331	54	393	301	51
CD4/8	0.55	0.30	0.11	0.47	0.27	0.09
Viral Load	99771	65424	22646	87366	30000	21720

TABLE 16: IMMUNOLOGICAL/VIROLOGICAL PARAMETERS AT 18 MONTHS CONTROLLING FOR PATIENTS BY CD4 COUNTS AT BASELINE

PARAMETER	CD4<500 (N=22)			CD4>500 (N=11)		
	MEAN			MEAN		
	Baseline	18 months	MEDIAN	Baseline	18 months	MEDIAN
CD4	265	238	269	805	703	769
CD4/8 ratio	0.35	0.27	0.24	0.95	0.88	0.60
Viral Load	141975	120335	102000	15363	21430	9010
				63708		2323

TABLE 17: PATIENTS WITH ABSOLUTE REDUCTION IN VIRAL LOAD AT 18 MONTHS (N=21)

PARAMETERS	BASELINE			18 MONTHS		
	MEAN			MEAN		
	MEAN	MEDIAN	STD ERROR OF MEAN	MEAN	MEDIAN	STD ERROR OF MEAN
CD4	478	331	74	384	301	63
CD4/8	0.55	0.33	1.3	0.47	0.29	0.10
Viral Load	101895	67186	27439	41241	16236	13924

TABLE 18: IMMUNOLOGICAL/VIROLOGICAL DATA BY GENDER (MALE=11, FEMALE=22) AT 18 MONTHS

PARAMETER	BASELINE						18 MONTHS					
	MEAN			MEDIAN			MEAN			MEDIAN		
	M	F	M	M	F	M	M	F	M	M	F	
CD4	318	478	288	288	331	307	307	384	302	301	301	
CD4/8	0.53	0.27	0.27	0.27	0.33	0.42	0.42	0.47	0.24	0.29	0.29	
Viral Load	175439	128106	128106	128106	67186	94962	94962	41242	28118	16236	16236	

TABLE 19: CONTROLLING FOR PATIENTS SHOWING ABSOLUTE VIRAL LOAD REDUCTION AT 18 MONTHS W.R.T. BASELINE

PARAMETER	PARAMETRIC MEANS					
	PATIENTS SHOWING VIRAL LOAD REDUCTION (N=22) = 67% OF COHORT			PATIENTS SHOWING VIRAL LOAD INCREASE (N=11) = 33% OF COHORT		
	BASELINE	18 MONTHS	% DIFFERENCE	BASELINE	18 MONTHS	% DIFFERENCE
WHO CLASS	2.27	1.23	-46%	2.25	1.36	-40%
CD4 Counts	484	409	-15%	367	362	-1%
CD4/8 ratio	0.62	0.56	-10%	0.33	0.30	-9%
Viral Load	97,319	39,372	-60%	104,776	168,246	+61%

TABLE 20: CONTROLLING FOR PATIENTS SHOWING ABSOLUTE VIRAL LOAD REDUCTION AT 24 MONTHS W.R.T. BASELINE

PARAMETER	PARAMETRIC MEANS					
	PATIENTS SHOWING VIRAL LOAD REDUCTION (N=16) = 52% OF COHORT			PATIENTS SHOWING VIRAL LOAD INCREASE (N=15) = 48% OF COHORT		
	BASELINE	24 MONTHS	% DIFFERENCE	BASELINE	24 MONTHS	% DIFFERENCE
CD4 Counts	482	480	-0.4%	317	356	+12%
CD4/8 ratio	0.59	0.62	+5%	0.41	0.37	-10%
Viral Load	64,005	32,216	-50%	89,932	204,549	+127%

TABLE 21: CONTROLLING FOR PATIENTS SHOWING ABSOLUTE VIRAL LOAD REDUCTION AT 30 MONTHS W.R.T. BASELINE

PARAMETER	PARAMETRIC MEANS					
	PATIENTS SHOWING VIRAL LOAD REDUCTION (N=24,82.8% OF COHORT)		PATIENTS SHOWING VIRAL LOAD INCREASE (N=5, 17.2% OF COHORT)		DIFFERENCE	
	BASELINE	30 MONTHS	BASELINE	30 MONTHS	DIFFERENCE	DIFFERENCE
CD4 Counts	498± 341 (R = 99-1339)	457± 397 (R = 23 - 1777)	327± 145 (R=211-525)	210± 157 (R=60-471)	-41	-117
CD4/8 ratio	0.61± 0.65 (R=0.04-2.40)	0.49± 0.54 (R=0.03-2.09)	0.38± 0.21 (R=0.14-0.61)	0.20± 0.1 (R=0.12-0.36)	-0.12	0.18
Body Mass Index BMI (KG/M ²)	24.4± 4.40 (R=18.9-36.1)	25.15± 4.07 (R=19.8-36.3)	23.96± 3.76 (R=19.9-27.6)	22.86± 3.37 (R=19.9-28.2)	+0.75	-1.1
Log Viral Load	4.345± 1.036 (R = 1.982 -5.684)	3.443± 1.10 (R = 1.699- 5.594)	4.553± 0.405 (R = 3.966- 4.979)	4.863± 0.431 (R=4.393- 5.544)	-0.912 (Highly significant reduction)	+0.310 (Increase is insignificant)

Key: R= Range

TABLE 22: CONTROLLING FOR PATIENTS SHOWING ABSOLUTE VIRAL LOAD REDUCTION AT 36 MONTHS W.R.T. BASELINE

PARAMETER	PARAMETRIC MEANS					
	PATIENTS SHOWING VIRAL LOAD REDUCTION (N= 20, 74.0% OF COHORT)		PATIENTS SHOWING VIRAL LOAD INCREASE (N=7, 26% OF COHORT)		DIFFERENCE	
	BASELINE	36 MONTHS	BASELINE	36 MONTHS	P-Value (Two-tailed)	P-Value (Two-Tailed)
CD4 Counts	534± 338	431± 307	370± 243	259± 212	0.015	0.026
CD4/8 ratio	0.65± 0.70	0.56± 0.56	0.43± 0.28	0.28± 0.17	0.160	0.017
Log Viral Load	4.24± 1.06	3.31± 1.15	4.57± 0.60	4.69± 0.58	0.000	0.012

OBSERVATIONS

- Clinically, results are still as remarkable at 36 months as at 3, 6, 9, 12, 18, 24, 27 and 30 months of evaluation.
- While the overall viral load reduction at 36 months is the highest ever experienced in the study (62.8%), 74% of the patients experienced absolute viral load reduction compared to baseline readings (Table 22). It is notable that the mean viral load of the majority of the patients reduced from log₄2.24 to log₃3.31 (P=0.000), giving a mean difference of log 0.93 that was significant.
- Patients who are performing better at 36 months are those who started off with higher CD4 counts and CD4/8 ratios (Table 22).
- At 36 months, VIUSID has no demonstrated clinical side effects to the patients.
- Patients number 22, 36, 46 and 33, who died of various chest complications during the study were found to have had a poor compliance of VIUSID intake. However, patient number 10, and 30 died at 22 and 28 months respectively; having changed from use of VIUSID to ARVs and herbal medicines respectively.
- However, despite all patients on the trial showing clinical improvements, 26% of them have experienced insignificant absolute increases in their viral loads.

CONCLUSIONS

- VIUSID has continued to show its efficacy at 36 months of follow-up of the patients, thereby presenting itself as a nutritional intervention with potential long term benefits in HIV/AIDS management in the region. It is particularly notable that no adverse side effects have been demonstrated following the use of VIUSID for 36 months.
- The death of patient number 10, 22, 30, 36 and 46 who poorly complied with intake of VIUSID could be a pointer at the usefulness of VIUSID in sustaining the lives of HIV patients who were consistent in using the product as instructed.
- The observation that eight patients (30%) have reduced or maintained their viral loads at below 1,000 copies over the 36 months of follow-up using VIUSID does demonstrate that this product may have long term benefits to users, especially those at the early stages of disease progression. Thus, it may be useful to persons diagnosed sero-positive Voluntary Testing and Counselling (VCT) centres which are being set-up countrywide to promote early diagnosis for effective management. It is also notable that even patients with low CD4 counts and high viral loads at baseline also benefited significantly from the use of VIUSID.
- Overall, this study is showing that this nutritional intervention could play a major role in the long-term management of HIV/AIDS patients in Kenya and in other parts of Sub-Saharan Africa.
- The logical step in this study is to continue observing the patients as potential long-term benefits are indicated from the 30 months results.

ACKNOWLEDGEMENTS

Director General, Catalysis is acknowledged for developing the product VIUSID and giving KEMRI a chance and support to evaluate its efficacy.

Director, KEMRI for supporting the conduct of the Study in Kenya.

Director Centre for Public Health Research, KEMRI for assisting with the proposal development and project implementation.

The Director, TAPWAK and all his assistance in proposal development and provision of research personnel. (members who supported the Study and by providing office space and patients for the clinical trial.

Ms. Galya Suslova, Export Director, Catalysis for establishing the contacts between KEMRI and Catalysis.

The following are also acknowledged for their technical contributions towards this study:

Dr. Peter Tukei, MSc. (Virologist) -KEMRI

1. Mr. Justus Omondi, Dip (Statistician/Data Entry) -KEMRI
2. Dr. Solomon Mpoke PhD (Immunology)- KEMRI
3. Mr. James Muthotho (Microbiologist)- KEMRI
4. Mr. Erastus Muniu – MSc. (Biostatistician) KEMRI
5. Mrs. Magdalene Kinyanjui (Laboratory Technologist) – KEMRI
6. Miss Lucy Kanyara (Laboratory Technologist) – KEMRI
7. Mrs. Margaret Mburu (Laboratory Technologist) - KEMRI
8. Miss Concepta Brenda Acom (Secretary) – KEMRI
9. Mrs. Monica Achieng (Secretary) – KEMRI
10. Miss Florence Musungu (Messenger) - KEMRI